Semaglutide Weight Management and Cardiovascular Risk Reduction
Strategic Aspirations 2025 | Today with emphasis on Innovation
and therapeutic focus
Purpose and
sustainability
(ESG)
لك
Commercial
execution
Progress towards zero environmental impact
Being respected for adding value to society
Being recognised as a sustainable employer
Strengthen Diabetes leadership - aim at global value
market share of more than 1/3
More than 25 billion DKK in Obesity sales by 2025
Secure a sustained growth outlook for Rare disease
CVD: Cardiovascular disease; NASH: Non-alcoholic steatohepatitis; CKD: Chronic kidney disease.
Note: The strategic aspirations are not a projection of Novo Nordisk's financial outlook or expected growth.
Financials
therapeutic focus
Innovation and
OIIIII
•
Further raise the innovation-bar for diabetes
treatment
Develop a leading portfolio of superior treatment
solutions for obesity
Strengthen and progress the Rare disease pipeline
Establish presence in Other serious chronic diseases
focusing on CVD, NASH and CKD
Deliver solid sales and operating profit growth
⚫ Drive operational efficiencies across the value chain to
enable investments in future growth assets
⚫ Deliver free cash flow to enable attractive capital
allocation to shareholdersView entire presentation